The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time

References

• Alemu AS, Kempker RR, Tenna A, et al. (2013). High prevalence of cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia. PLoS One 8:e58377
   PubMed Web of Science ®Google Scholar
• Babady NE, Bestrom JE, Jespersen DJ, et al. (2009). Evaluation of three commercial latex agglutination kits and a commercial enzyme immunoassay for the detection of cryptococcal antigen. Med Mycol 47:336–8
   PubMed Web of Science ®Google Scholar
• Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. (2012). Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol 19:1988–90
   PubMed Web of Science ®Google Scholar
• Boulware DR, Rolfes MA, Rajasingham R, et al. (2014). Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 20:45–53
   PubMed Web of Science ®Google Scholar
• Butler EK, Boulware DR, Bohjanen PR, Meya DB. (2012). Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One 7:e51291
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention; National Center for Zoonotic, V.-B. a. E. D. 2010. Cryptococcus. Available from: http://www.cdc.gov/nczved/divisions/dfbmd/diseases/cryptococcus/technical.html [last accessed 22 April 2011]
   Google Scholar
• Denning DW, Armstrong RW, Lewis BH, Stevens DA. (1991). Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 91:267–72
   PubMed Web of Science ®Google Scholar
• Diamond RD, Bennett JE. (1974). Prognostic factors in cryptococcal meningitis. Ann Intern Med 80:176–81
   PubMed Web of Science ®Google Scholar
• Dromer F, Aucouturier P, Clauvel JP, et al. (1988). Cryptococcus neoformans antibody levels in patients with AIDS. Scand J Infect Dis 20:283–5
   PubMed Web of Science ®Google Scholar
• Escandon P, Lizarazo J, Agudelo CI, et al. (2013). Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia. Med Mycol 51:765–8
   PubMed Web of Science ®Google Scholar
• French N, Gray K, Watera C, et al. (2002). Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16:1031–8
   PubMed Web of Science ®Google Scholar
• Galanis E, Macdougall L, Kidd S, Morshed M. (2010). Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007. Emerg Infect Dis 16:251–7
   PubMed Web of Science ®Google Scholar
• Garcia-Hermoso D, Janbon G, Dromer F. (1999). Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 37:3204–9
   PubMed Web of Science ®Google Scholar
• Gates-Hollingsworth MA, Kozel TR. (2013). Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen (CrAg). Clin Vaccine Immunol 20:634–5
   PubMed Web of Science ®Google Scholar
• Hamilton JR, Noble A, Denning DW, Stevens DA. (1991). Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 29:333–9
   PubMed Web of Science ®Google Scholar
• Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. (2013). Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 20:52–5
   PubMed Web of Science ®Google Scholar
• Harris JR, Lockhart SR, Debess E, et al. (2011). Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 53:1188–95
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Govender N, Chiller T, et al. (2012). Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation J Internat Assoc Physicians AIDS Care 11:374–9
   Google Scholar
• Jarvis JN, Harrison TS, Govender N, et al. (2011a). Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts–time to implement in South Africa? S Afr Med J 101:232–4
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Lawn SD, Vogt M, et al. (2009). Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48:856–62
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Percival A, Bauman S, et al. (2011b). Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53:1019–23
   PubMed Web of Science ®Google Scholar
• Kabanda T, Siedner MJ, Klausner JD, et al. (2014). Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis 58:113–16
   PubMed Web of Science ®Google Scholar
• Karstaedt AS, Crewe-Brown HH, Dromer F. (2002). Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South Africa. Med Mycol 40:7–11
   PubMed Web of Science ®Google Scholar
• Kozel TR, Bauman SK. (2012). CrAg lateral flow assay for cryptococcosis. Expert Opin Med Diagn 6:245–51
   PubMedGoogle Scholar
• Kwizera R, Nguna J, Kiragga A, et al. (2014). Performance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100. PLoS One 9:e103156
   PubMed Web of Science ®Google Scholar
• Lawn SD, Myer L, Harling G, et al. (2006). Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43:770–6
   PubMed Web of Science ®Google Scholar
• Lessells RJ, Mutevedzi PC, Heller T, Newell ML. (2011). Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S Afr Med J 101:251–2
   PubMed Web of Science ®Google Scholar
• Liechty CA, Solberg P, Were W, et al. (2007). Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12:929–35
   PubMed Web of Science ®Google Scholar
• Lindsley MD, Mekha N, Baggett HC, et al. (2011). Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53:321–5
   PubMed Web of Science ®Google Scholar
• Litvintseva AP, Thakur R, Reller LB, Mitchell TG. (2005). Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 192:888–92
   PubMed Web of Science ®Google Scholar
• Magambo KA, Kalluvya SE, Kapoor SW, et al. (2014). Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania. J Internat AIDS Soc 17:19040–5
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K, et al. (2010). Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 50:1532–8
   PubMed Web of Science ®Google Scholar
• McKenney J, Smith R, Chiller T, et al. (2014). Prevalence and correlates of cryptococcal antigen positivity among AIDS patients – United States, 1986–2012. Morb Mortal Wkly Rep 63:585–7
   PubMed Web of Science ®Google Scholar
• McMullan BJ, Halliday C, Sorrell TC, et al. (2012). Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 7:e49541
   PubMed Web of Science ®Google Scholar
• Meya DB, Manabe YC, Castelnuovo B, et al. (2010). Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51:448–55
   PubMed Web of Science ®Google Scholar
• Meyer AC, Kendi CK, Penner JA, et al. (2013). The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health 18:495–503
   PubMed Web of Science ®Google Scholar
• Micol R, Lortholary O, Sar B, et al. (2007). Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45:555–9
   PubMed Web of Science ®Google Scholar
• Micol R, Tajahmady A, Lortholary O, et al. (2010). Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 5:e13856
   PubMed Web of Science ®Google Scholar
• Park BJ, Wannemuehler KA, Marston BJ, et al. (2009). Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525–30
   PubMed Web of Science ®Google Scholar
• Percival A, Thorkildson P, Kozel TR. (2011). Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen. Clin Vaccine Immunol 18:1292–6
   PubMed Web of Science ®Google Scholar
• Pongsai P, Atamasirikul K, Sungkanuparph S. (2010). The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 60:474–7
   PubMed Web of Science ®Google Scholar
• Pyrgos V, Seitz AE, Steiner CA, et al. (2013). Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS One 8:e56269
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Boulware DR. (2012). Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL. Clin Infect Dis 55:1742–4
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Meya DB, Boulware DR. (2012). Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59:e85–91
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Filler SG, Chetchotisakd P, et al. (2009). Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 49:931–4
   PubMed Web of Science ®Google Scholar
• Vijayan T, Chiller T, Klausner JD. (2013). Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs 45:16–20
   PubMedGoogle Scholar
• World Health Organization. (2011, December). Rapid advice on the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: WHO
   Google Scholar
• Worodria W, Massinga-Loembe M, Mazakpwe D, et al. (2011). Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 58:32–7
   PubMed Web of Science ®Google Scholar
• Zuger A, Louie E, Holzman RS, et al. (1986). Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of therapy. Ann Intern Med 104:234–40
   PubMed Web of Science ®Google Scholar